Phathom Pharmaceuticals, Inc. Long-term assets (Other)

Long-term assets (Other) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-term assets (Other) growth rates and interactive chart. All other non-current assets that do not fit the categories above.


Highlights and Quick Summary

  • Long-term assets (Other) for the quarter ending September 29, 2021 was $341 Thousand (a 17.18% increase compared to previous quarter)
  • Year-over-year quarterly Long-term assets (Other) decreased by -11.2%
  • Annual Long-term assets (Other) for 2020 was $384 Thousand (a 112.15% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-term assets (Other) of Phathom Pharmaceuticals, Inc.

Most recent Long-term assets (Other)of PHAT including historical data for past 10 years.

Interactive Chart of Long-term assets (Other) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Long-term assets (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.34 $0.29 $0.39
2020 $0.38 $0.38 $0.38 $0.38 $0.38
2019 $0.18 $2.01 $0.18

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.